Skip to content

Effect of Smartphone Based Telemedicine and Education in Patients With Type 1 Diabetes Mellitus

Effect of Smartphone Based Telemedicine and Education in Patients With Type 1 Diabetes Mellitus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04721509
Enrollment
100
Registered
2021-01-22
Start date
2021-02-28
Completion date
2022-09-30
Last updated
2021-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

Diabetes Mellitus, Telemedicine, Smartphone, Type 1, Child, Adolescent, Young Adult

Brief summary

Objective: evaluation of effect of smartphone based telemedicine and education in patients with type 1 diabetes mellitus Outline: Among the patients with type 1 diabetes, the group with telemedicine and education using smartphone set as a experimental group and the group without those set as a control group, respectively. Sample size: experimental group (n=50), control group (n=50) Inclusion criteria: patients with type 1 diabetes with A1c\>8.0% Exclusion criteria: chronic disease, psychological disease, children aged under 12 with parents with psychological disease, athletics Method: We divide subjects as an experimental group and a control group by randomization, and they visit outpatient clinic every 12 weeks. We perform telemedicine and education with smartphone application to the experimental group every 2 weeks. We evaluate the effect of smartphone based telemedicine and education in patients with type 1 diabetes mellitus with checking A1c and checklist at baseline, 12 weeks and 24 weeks after starting of the research. Variables: A1c, satisfaction, knowledge, self-confidence, willing to continuing, quality of life, physical activity, drinking, smoking Primary endpoint: Improvement in HbA1c of experimental group Secondary endpoint: No improvement in HbA1c of control group

Interventions

DEVICEExperimental : Smartphone-based telemedicine with the app 'Songaree diabetes'

Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Masking description

Open label

Intervention model description

Inclusion criteria: patients with type 1 diabetes with A1c\>8.0% Exclusion criteria: chronic disease, psychological disease, children aged under 12 with parents with psychological disease, athletics Method: We divide subjects as an experimental group and a control group by randomization, and they visit outpatient clinic every 12 weeks. We perform telemedicine and education with smartphone application to the experimental group every 2 weeks. We evaluate the effect of smartphone based telemedicine and education in patients with type 1 diabetes mellitus with checking A1c and checklist at baseline, 12 weeks and 24 weeks after starting of the research.

Eligibility

Sex/Gender
ALL
Age
0 Months to 30 Years
Healthy volunteers
No

Inclusion criteria

a. patients aged under 30 with type 1 diabetes b. patients who control glucose level with multiple daily injection of insulin pump c. Patients who agree the task to check glucose level during the experiment d. patients who has been diagnosed as type 1 diabetes more than 3 months e. patients whose A1c more than 8.0% within 6 months f. Patients who can use smartphone all day 2)

Exclusion criteria

1. chronic disease (except thyroid disorders with euthyroidism), psychological disease 2. Patients aged under 12 whose parents have psychological disease 3. Patients who cannot use smartphone app properly 4. athletics 5. Patients who use continuous glucose monitoring

Design outcomes

Primary

MeasureTime frame
change in HbA1c of experimental group6 months

Secondary

MeasureTime frame
No change in HbA1c of control group6 months later

Countries

South Korea

Contacts

Primary ContactHo-Seong Kim
kimho@yuhs.ac82-2-2228-2050

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026